PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ChatGPT outperformed trainee doctors in assessing complex respiratory illness in children

2024-09-09
(Press-News.org) The chatbot ChatGPT performed better than trainee doctors in assessing complex cases of respiratory disease in areas such as cystic fibrosis, asthma and chest infections in a study presented at the European Respiratory Society (ERS) Congress in Vienna, Austria [1].

 

The study also showed that Google’s chatbot Bard performed better than trainees in some aspects and Microsoft’s Bing chatbot performed as well as trainees.

 

The research suggests that these large language models (LLMs) could be used to support trainee doctors, nurses and general practitioners to triage patients more quickly and ease pressure on health services.

 

The study was presented by Dr Manjith Narayanan, a consultant in paediatric pulmonology at the Royal Hospital for Children and Young People, Edinburgh and honorary senior clinical lecturer at the University of Edinburgh, UK. He said: “Large language models, like ChatGPT, have come into prominence in the last year and a half with their ability to seemingly understand natural language and provide responses that can adequately simulate a human-like conversation. These tools have several potential applications in medicine. My motivation to carry out this research was to assess how well LLMs are able to assist clinicians in real life.”

 

To investigate this, Dr Narayanan used clinical scenarios that occur frequently in paediatric respiratory medicine. The scenarios were provided by six other experts in paediatric respiratory medicine and covered topics like cystic fibrosis, asthma, sleep disordered breathing, breathlessness and chest infections. They were all scenarios where there is no obvious diagnosis, and where there is no published evidence, guidelines or expert consensus that point to a specific diagnosis or plan.

 

Ten trainee doctors who had less than four months of clinical experience in paediatrics were given an hour where they could use the internet, but not any chatbots, to solve each scenario with a descriptive answer of 200 to 400 words. Each scenario was also presented to the three chatbots.

 

All the responses were scored by six paediatric respiratory experts for correctness, comprehensiveness, usefulness, plausibility, and coherence. They were also asked to say whether they thought each response was human- or chatbot-generated and to give each response an overall score out of nine.

 

Solutions provided by ChatGPT version 3.5 scored an average of seven out of nine overall and were believed to be more human-like than responses from the other chatbots. Bard scored an average of six out of nine and was scored as more ‘coherent’ than trainee doctors, but in other respects was no better or worse than trainee doctors. Bing scored an average of four out of nine – the same as trainee doctors overall. Experts reliably identified Bing and Bard responses as non-human.

 

Dr Narayanan said: “Our study is the first, to our knowledge, to test LLMs against trainee doctors in situations that reflect real-life clinical practice. We did this by allowing the trainee doctors to have full access to resources available on the internet, as they would in real life. This moves the focus away from testing memory, where there is a clear advantage for LLMs. Therefore, this study shows us another way we could be using LLMs and how close we are to regular day-to-day clinical application.

 

“We have not directly tested how LLMs would work in patient facing roles. However, it could be used by triage nurses, trainee doctors and primary care physicians, who are often the first to review a patient.”

 

The researchers did not find any obvious instances of ‘hallucinations’ (seemingly made-up information) with any of the three LLMs. “Even though, in our study, we did not see any instance of hallucination by LLMs, we need to be aware of this possibility and build mitigations against this,” Dr Narayanan added. Answers that were judged to be irrelevant to the context were occasionally given by Bing, Bard and the trainee doctors.

 

Dr Narayanan and his colleagues are now planning to test chatbots against more senior doctors and to look at newer and more advanced LLMs.

 

Hilary Pinnock is ERS Education Council Chair and Professor of Primary Care Respiratory Medicine at The University of Edinburgh, UK, and was not involved in the research. She says: “This is a fascinating study. It is encouraging, but maybe also a bit scary, to see how a widely available AI tool like ChatGPT can provide solutions to complex cases of respiratory illness in children. It certainly points the way to a brave new world of AI-supported care.

 

“However, as the researchers point out, before we start to use AI in routine clinical practice, we need to be confident that it will not create errors either through ‘hallucinating’ fake information or because it has been trained on data that does not equitably represent the population we serve. As the researchers have demonstrated, AI holds out the promise of a new way of working, but we need extensive testing of clinical accuracy and safety, pragmatic assessment of organisational efficiency, and exploration of the societal implications before we embed this technology in routine care.”

END


ELSE PRESS RELEASES FROM THIS DATE:

Night owls are more likely to develop type 2 diabetes – and it’s not just because of an unhealthy lifestyle, Dutch study finds

2024-09-09
Night owls have a higher BMI, larger waists, more hidden body fat and are almost 50% more likely to develop type 2 diabetes (T2D) than those who go to bed earlier, new research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), has found. Lead researcher Dr Jeroen van der Velde, of Leiden University Medical Centre, Leiden, Netherlands, says: “Previous studies have indicated that a late chronotype – preferring to go to bed late and wake up later – is associated with an unhealthy lifestyle. Late chronotypes are ...

Air travel may affect insulin pump delivery in people with type 1 diabetes

2024-09-09
Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated with insulin pump therapy, according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept). “We investigated the effect atmospheric pressure changes during flight can have on insulin pumps following concerns that glucose levels may drop below the normal ranges during or immediately after flights,” explained lead author Dr Ka Siu Fan from the Royal Surry County Hospital and University ...

Fruit and oats raise risk of type 1 diabetes but berries provide protection, research suggests

2024-09-09
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), shows that eating fruit, oats and rye in childhood is associated with a higher risk of developing type 1 diabetes (T1D). Eating berries, however, is linked to lower odds of developing the condition. T1D is an autoimmune condition in which the immune system attacks and destroys the insulin-producing islet cells in the pancreas.  This prevents the body from producing enough of the hormone insulin to properly regulate blood sugar levels. What triggers the immune system’s attack is unknown but is thought to involve a combination ...

Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found

2024-09-09
Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear. Glucocorticoids (sometimes known as steroids) fight inflammation and are used to treat a wide range of inflammatory and autoimmune conditions, including asthma, rheumatoid arthritis, cancers and other medical problems. While they can be very effective in decreasing inflammation, glucocorticoids have many adverse effects including ...

Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC

Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC
2024-09-08
(San Diego, Calif--September 8, 2024, 10:05 a.m. PCT) – New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who received adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery compared to those who received only neoadjuvant nivolumab plus chemotherapy. The data was reported at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. This is the first analysis of individual patient-level data from two phase 3 trials, CheckMate 77T and CheckMate 816, to examine which patients may derive benefit from ...

PanCan nodule management protocol more effective than LungRADSv1.1 method

PanCan nodule management protocol more effective than LungRADSv1.1 method
2024-09-08
(San Diego, Calif.--September 8, 2024, 10:05 a.m. PCT) – New data presented today reveals that the PanCan nodule management protocol demonstrates superior performance in triaging lung cancer screening participants compared to the LungRADSv1.1 approach. Specifically, PanCan showed improved risk stratification and  reduced the number of low-dose computed tomography(CT) scans required. The research was reported by Dr. Annette McWilliams, Fiona Stanley Hospital, Australia at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. The ...

Normalized membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes in TROPION-Lung 01

Normalized membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes in TROPION-Lung 01
2024-09-08
(San Diego, Calif.--September 8, 2024, 10:05 a.m. PCT) – New data presented today demonstrate that TROP2 expression as measured by quantitative continuous scoring (QCS), a computational pathology approach, is a promising predictor of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated with the TROP2 antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). The data showed that patients with TROP2 positivity, as determined by QCS, experienced improved efficacy with Dato-DXd compared to patients receiving docetaxel ...

Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive advanced NSCLC in HARMONi-2 study

Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive advanced NSCLC in HARMONi-2 study
2024-09-08
(San Diego, Calif--September 8, 2024, 8:30 a.m.) — Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer.  The results were presented today at  the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer. The HARMONi-2 study randomized 398 patients ...

NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC -- Data builds on AEGEAN study research

NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC -- Data builds on AEGEAN study research
2024-09-08
(San Diego, Calif. September 8, 2024 10:05 a.m. PCT) – Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens. The data was presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer by Dr. Tina Cascone, from The University of Texas MD Anderson Cancer Center in Houston. “The findings highlight the potential of combining durvalumab with novel anticancer agents to build on what we have learned in the perioperative immunotherapy arena for patients with ...

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence
2024-09-08
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators. For the study, researchers compared health outcomes among 147 participants in the CheckMate 816 study — in which patients received three cycles of the immunotherapy nivolumab plus chemotherapy before surgery (neoadjuvant) — with results of 139 participants in the CheckMate 77T trial, in which patients received up to four cycles of nivolumab plus chemotherapy ...

LAST 30 PRESS RELEASES:

Getting to the root of the problem: Intensive diabetes treatment reduces gum disease inflammation

Researchers take power and efficiency of biological sensing to record level

Under-plant mirrors improve endangered plant survival and growth

Widespread evidence for packaging-related chemicals in humans

Hardship early in life can affect health and longevity – even for marmots

Chances of successful pregnancy are the same with embryo transfer on day three or five

The Lancet: More than 39 million deaths from antibiotic-resistant infections estimated between now and 2050, suggests first global analysis

Fraunhofer IAF low-noise amplifiers aboard the Arctic Weather Satellite

Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer

US COVID-19 rates oscillate every six months

Lower neighborhood opportunity may increase risk for preterm birth

Analysis finds cardiac devices recalled for safety reasons infrequently subjected to premarket or postmarket testing

Trailblazers in plasma turbulence computer simulations win 2024 James Clerk Maxwell Prize

Technology could boost renewable energy storage

Introducing SandAI: A tool for scanning sand grains that opens windows into recent time and the deep past

Critical crops’ alternative way to succeed in heat and drought

Students with multiple marginalized identities face barriers to sports participation

Purdue deep-learning innovation secures semiconductors against counterfeit chips

Will digital health meet precision medicine? A new systematic review says it is about time

Improving eye tracking to assess brain disorders

Hebrew University’s professor Haitham Amal is among a large $17 million grant consortium for pioneering autism research

Scientists mix sky’s splendid hues to reset circadian clocks

Society for Neuroscience 2024 Outstanding Career and Research Achievements

Society for Neuroscience 2024 Early Career Scientists’ Achievements and Research Awards

Society for Neuroscience 2024 Education and Outreach Awards

Society for Neuroscience 2024 Promotion of Women in Neuroscience Awards

Baek conducting air quality monitoring & simulation analysis

Albanese receives funding for scholarship grant program

Generative AI model study shows no racial or sex differences in opioid recommendations for treating pain

New study links neighborhood food access to child obesity risk

[Press-News.org] ChatGPT outperformed trainee doctors in assessing complex respiratory illness in children